Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.75.3ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.2.75.3ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XAKORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XAKORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XAAORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XAAORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BQ.1.30ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BQ.1.30ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BQ.1.1.50ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BQ.1.1.50ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.5.1.36ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.5.1.36ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XBB.1.23ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XBB.1.23ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-15630.5France
XBB.1.38.1ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XBB.1.38.1ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
N/AORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
N/AORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XAANSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-19568.4US
BQ.1.30NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BQ.1.1.50NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.1.36NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.23NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.38.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
N/ANSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.42.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.348NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.428.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AJ.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
B.1.459NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.160.29NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.415.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.243.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.98NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
B.1.566NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.480NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.579NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
N.10NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
P.1.11 (Gamma)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.435NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.445NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.124NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.384NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
XAQNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.3.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.569NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.524NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
A.23NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.596.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.473NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used